{"id":"W1565820605","doi":"10.1158/1538-7445.sabcs14-s3-01","title":"Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or <i>BRCA1/2</i> breast cancer (CRUK/07/012)","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":166,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Oncology; Internal medicine; Docetaxel; Carboplatin; Metastatic breast cancer; Breast cancer; Taxane; Clinical endpoint; Triple-negative breast cancer; Progression-free survival; Chemotherapy; Anthracycline; Chemotherapy regimen; Randomized controlled trial; Cancer; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002316617,0.0003849364,0.001060599,0.0001110069,0.0001739617,0.00006417813,0.0005482383,0.0001120752,0.0001246148],"category_scores_gemma":[0.0009808709,0.0001922135,0.0002008391,0.0004698853,0.0005767138,0.00002573963,0.0001340469,0.0003307706,0.000001899133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002172076,"about_ca_system_score_gemma":0.003291432,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009008322,"about_ca_topic_score_gemma":0.0024599,"domain_scores_codex":[0.9959367,0.0007171729,0.0007687675,0.0007249085,0.001139931,0.0007125162],"domain_scores_gemma":[0.9961279,0.0005768873,0.0005480748,0.0006822867,0.001748001,0.0003168499],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9792563,0.001202801,0.000003138667,0.0001127025,0.0007822715,0.000006016353,0.000440911,0.0003006605,0.008097945,0.00001383992,0.002313592,0.007469843],"study_design_scores_gemma":[0.9435412,0.01080098,0.00000629783,0.0002406061,0.0002316211,0.000003368453,0.0006181625,0.0002999618,0.04209641,0.00008382317,0.001760022,0.0003175981],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9801859,0.0006887914,0.001026265,0.0003774349,0.0005065543,0.01587634,0.001175958,0.0000226443,0.0001401543],"genre_scores_gemma":[0.9872733,0.0003083446,0.001236899,0.00007606682,0.0003053093,0.009788471,0.0001863272,0.0000895938,0.0007356739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03571512,"threshold_uncertainty_score":0.783824,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07511545520705774,"score_gpt":0.3992765637296873,"score_spread":0.3241611085226295,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}